• It's a rare thing, to observe someone and feel like you're tuning into the same unspoken melody. Not a grand symphony, just a quiet, resonant hum that suggests deeper harmonies. It makes you wonder about the conversations you haven't had yet. Sara Sampaio, june 2025
    It's a rare thing, to observe someone and feel like you're tuning into the same unspoken melody. Not a grand symphony, just a quiet, resonant hum that suggests deeper harmonies. It makes you wonder about the conversations you haven't had yet. 🎶✨Sara Sampaio, june 2025
    Like
    Love
    Wow
    · 0 Commenti ·0 condivisioni ·58K Views ·0 Anteprima
  • Sara Sampaio, june 2025
    Sara Sampaio, june 2025
    Like
    Love
    Wow
    · 0 Commenti ·0 condivisioni ·57K Views ·0 Anteprima
  • Am I late …?🥹

    Been too busy during June and finally had time to settle my birthday party which is by this Sunday Was busy moving home during June! Making a more casual birthday party this year

    Will be bringing Egg Tart as my special guest this year!
    Been always wanting to try a green theme (I love green) and finally it’s a dream come true for me (终于实现了绿色主题的梦想!

    There are two Google Forms, check out my birthday merch by scrolling to last! Huhu

    Thank you for the birthday wishes last month Let’s celebrate properly again this Sunday! Love you 🙆🏼‍♀️
    Am I late …?🥹💕 Been too busy during June and finally had time to settle my birthday party which is by this Sunday 🙈💕 Was busy moving home during June! Making a more casual birthday party this year 😗💕 Will be bringing Egg Tart🐱 as my special guest this year! Been always wanting to try a green theme (I love green) and finally it’s a dream come true for me🙈💕 (终于实现了绿色主题的梦想! There are two Google Forms, check out my birthday merch by scrolling to last! Huhu😗💕 Thank you for the birthday wishes last month 💕 Let’s celebrate properly again this Sunday! Love you 🙆🏼‍♀️
    Like
    Love
    Wow
    · 0 Commenti ·0 condivisioni ·50K Views ·0 Anteprima
  • HARPER BAZAAR x CARTIER - Cover June 2024

    Creative Director: Trần Đạt.
    Photographer: Huỳnh Trí Nghĩa
    Producer: Duyên Nguyễn
    Stylist: #D2Styling Phương Nam
    Makeup: Dương Hữu Nghĩa.
    Hair: Nhất Linh
    HARPER BAZAAR x CARTIER - Cover June 2024 Creative Director: Trần Đạt. Photographer: Huỳnh Trí Nghĩa Producer: Duyên Nguyễn Stylist: #D2Styling Phương Nam Makeup: Dương Hữu Nghĩa. Hair: Nhất Linh
    Like
    Love
    Wow
    · 0 Commenti ·0 condivisioni ·47K Views ·0 Anteprima
  • In June 2025, the U.S. Food and Drug Administration (FDA) officially approved Yeztugo (lenacapavir) as the world’s first twice-yearly injection for HIV prevention (PrEP).

    Developed by Gilead Sciences, this landmark drug offers long-term protection from HIV with just two subcutaneous shots per year.

    The approval is based on extensive clinical trials under the PURPOSE 1 and 2 studies, which showed near-perfect efficacy—zero new infections in cisgender women and only two infections across a broader population of over 2,000 individuals.

    This brings its protective rate to approximately 99.9%, making it the most effective and long-acting HIV prevention method available today.

    Lenacapavir works by targeting the HIV capsid, a protein shell that encases the virus’s genetic material.

    By inhibiting this capsid, the drug prevents HIV from replicating inside human cells.

    Unlike daily oral PrEP options like Truvada or Descovy, Yeztugo is designed to overcome common adherence issues by requiring just one injection every six months. This simplifies prevention for at-risk

    populations, especially those who struggle with daily medication routines.

    While the approval is being hailed as a major victory in the global fight against HIV, access and affordability remain concerns.

    The U.S. list price for a year’s supply is expected to be around $28,000, though Gilead has committed to providing generics to 120 low-income countries and producing up to 10 million doses by 2026.

    Global health experts see this breakthrough as a turning point that could drastically reduce new HIV infections—if distribution is equitable and timely.

    In summary, Yeztugo's approval represents a critical milestone in HIV prevention science, combining exceptional efficacy, convenience, and innovation.

    It has the potential to reshape the future of HIV prevention—especially if healthcare systems can ensure widespread access to those most in need.
    In June 2025, the U.S. Food and Drug Administration (FDA) officially approved Yeztugo (lenacapavir) as the world’s first twice-yearly injection for HIV prevention (PrEP). Developed by Gilead Sciences, this landmark drug offers long-term protection from HIV with just two subcutaneous shots per year. The approval is based on extensive clinical trials under the PURPOSE 1 and 2 studies, which showed near-perfect efficacy—zero new infections in cisgender women and only two infections across a broader population of over 2,000 individuals. This brings its protective rate to approximately 99.9%, making it the most effective and long-acting HIV prevention method available today. Lenacapavir works by targeting the HIV capsid, a protein shell that encases the virus’s genetic material. By inhibiting this capsid, the drug prevents HIV from replicating inside human cells. Unlike daily oral PrEP options like Truvada or Descovy, Yeztugo is designed to overcome common adherence issues by requiring just one injection every six months. This simplifies prevention for at-risk populations, especially those who struggle with daily medication routines. While the approval is being hailed as a major victory in the global fight against HIV, access and affordability remain concerns. The U.S. list price for a year’s supply is expected to be around $28,000, though Gilead has committed to providing generics to 120 low-income countries and producing up to 10 million doses by 2026. Global health experts see this breakthrough as a turning point that could drastically reduce new HIV infections—if distribution is equitable and timely. In summary, Yeztugo's approval represents a critical milestone in HIV prevention science, combining exceptional efficacy, convenience, and innovation. It has the potential to reshape the future of HIV prevention—especially if healthcare systems can ensure widespread access to those most in need.
    Like
    Love
    Wow
    · 0 Commenti ·0 condivisioni ·42K Views ·0 Anteprima
Pagine in Evidenza